All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Treatment sequencing for anemic myelofibrosis

with Jean-Jacques Kiladjian & Angela Fleischman

Monday, February 26, 2024 | 16:30 CET

This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.


The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Promising new drugs in MPN therapy

Jan 17, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in myeloproliferative neoplasms.

Bookmark this article

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Pemmaraju, MD Anderson Cancer Center, Houston, US. We asked, what are some of the promising new drugs in MPN therapy?

Pemmaraju begins by outlining current therapies that are being successfully combined with Janus kinase inhibitors (JAKi) in the frontline treatment setting. These include navitoclax, pelabresib, and selinexor; each combined with the JAKi backbone therapy, ruxolitinib. He then discusses agents aimed at patients who experience suboptimal responses to initial JAKi therapy. Pemmaraju concludes by highlighting novel therapeutic approaches that move beyond the conventional JAKi approach. These include monoclonal antibodies, calreticulin mutant-specific targeting, and the discovery and targeting of novel signaling pathways.

What are some of the promising new drugs in MPN therapy?


Subscribe to get the best content related to MPN delivered to your inbox